Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-19-000011
Filing Date
2019-03-08
Accepted
2019-03-08 14:01:05
Documents
6
Period of Report
2018-12-31

Document Format Files

Seq Description Document Type Size
1 2018 FOURTH QUARTER 6-K q42018form6k.htm 6-K 21240
2 DECEMBER 31 2018 CONSOLIDATED FINANCIAL STATEMENTS oncyf2018-fsfor6k.htm EX-99.1 693830
3 DECEMBER 31 2018 MD&A ex151-2018mdafor6k.htm EX-99.2 460234
4 eysignaturea09.jpg GRAPHIC 7648
5 eysignaturea10.jpg GRAPHIC 7648
6 oncolyticslogotaglinebluea04.jpg GRAPHIC 367326
  Complete submission text file 0001129928-19-000011.txt   1654736
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 19668645
SIC: 2834 Pharmaceutical Preparations